IL22 and polycystic ovary syndrome: The top co-cited reference is Qi XY’s 2019 article in Nature Medicine, “Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome.” They suggest that modifications to the gut microbiome, alterations in bile acid metabolism, and/or enhancements in interleukin-22 (IL-22) levels may be advantageous for the treatment of PCOS (Qi et al., 2019).